Author

Ajay K. Nooka

Associate Professor, Division of Bone Marrow Transplant, Winship Cancer Institute, Emory University - Cited by 11,973 - Multiple myeloma - B- cell malignancies - Bone Marrow Transplant

Biography

Ajay K. Nooka, belonging to Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA. Interested in the field of Autologous stem cell transplantation, Health disparity.
Title
Cited by
Year
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ...New England Journal of Medicine 387 (6), 495-505, 2022202
168
2022
Ide-cel or standard regimens in relapsed and refractory multiple myeloma
P Rodriguez-Otero, S Ailawadhi, B Arnulf, K Patel, M Cavo, AK Nooka, ...New England Journal of Medicine 388 (11), 1002-1014, 2023202
41
2023
Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia
A Chang, A Akhtar, SL Linderman, L Lai, VM Orellana-Noia, ...Journal of Clinical Oncology 40 (26), 3020-3031, 2022202
23
2022
Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma
AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, ...Journal of Clinical Oncology 40 (26), 3057, 2022202
21
2022
Efficacy and safety of Elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-Cell Maturation Antigen (BCMA)-directed therapies: Results from cohort a of …
NJ Bahlis, MH Tomasson, M Mohty, R Niesvizky, AK Nooka, S Manier, ...Blood 140 (Supplement 1), 391-393, 2022202
19
2022
Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial
P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...Journal of Clinical Oncology 41 (8), 1600, 2023202
15
2023
Antibody response to COVID-19 mRNA vaccine in patients with lung cancer after primary immunization and booster: reactivity to the SARS-CoV-2 WT virus and Omicron variant
RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, ...Journal of Clinical Oncology 40 (33), 3808-3816, 2022202
10
2022
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough …
Impaired SARS-CoV-2 Variant Neutralization and CD+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough …MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, ...Blood Cancer Discovery 4 (2), 106-117, 2023202
8
2023
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 Trial
AK Nooka, A Cohen, HC Lee, AZ Badros, A Suvannasankha, N Callander, ...Blood 10 (Supplement 1), 7301-7303, 2022202
4
2022
Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
A Sharma, R Nair, A Achreja, A Mittal, P Gupta, K Balakrishnan, CL Edgar, ...Science Advances 8 (39), eabq5575, 2022202
4
2022
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
TG Martin, MV Mateos, A Nooka, A Banerjee, R Kobos, L Pei, M Qi, ...Cancer, 030
2
2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA. 4/5 following booster vaccination of patients with B-cell malignancies
Antibody binding and neutralization of live SARS-CoV- variants including BA. 4/5 following booster vaccination of patients with B-cell malignanciesA Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, ...Cancer research communications (1), 1684-169, 0
2
2022
African American race as a risk factor for developing peripheral neuropathy in newly diagnosed patients with multiple myeloma receiving bortezomib induction
L Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, ...Blood 140 (Supplement 1), 7131-713, 0
2
2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival
VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, ...Blood Cancer Journal 2 (8), 5, 2022202
1
2022
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis …
AK Nooka, AM Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, ...Journal of Clinical Oncology 4 (6_suppl), 8008-8008, 2023202
1
2023
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
CLL-55 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaA Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, ...Clinical Lymphoma Myeloma and Leukemia 22, S28-S282, 2022202
1
2022
Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders
H Robinson, N Villa, DL Jaye, AK Nooka, A Duffy, S McCachren, J Manalo, ...Blood 40 (Supplement ), 244-245, 2022202
1
2022
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, ...Blood Cancer Journal 3 (), 29, 2023202
1
2023
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
A Krishnan, AK Nooka, A Chari, AL Garfall, TG Martin, S Nair, X Lin, K Qi, ...Journal of Comparative Effectiveness Research, e22086, 2023202
1
2023
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.
AK Nooka, NS Joseph, MV Dhodapkar, CC Hofmeister, VA Gupta, ...Journal of Clinical Oncology 4 (6_suppl), 800-800, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=ScBEJRAAAAAJ&hl=en

Cited by
Citations 11973
h-index 45
i10-index 144
Recommended Journals
Open Access Journals